Ijudo IV infusion 25mg, from AstraZeneca, contains Tremelimumab (genetical recombination). This monoclonal antibody acts as an immune checkpoint inhibitor, blocking CTLA-4 to enhance T cell-mediated anti-tumor responses. It is supplied as 25mg in 1.25mL per bottle, with YJ code 4291465A1020.
Ijudo IV infusion 25mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).